Výsledky vyhledávání - "Natalie Marie Reizine"

Adverse events associated with androgen receptor signaling inhibitors in the treatment of prostate cancer: A systematic review and network meta-analysis

Autor: Brent Cao, Melissa Kim, Natalie Marie Reizine, Daniel Moreira

Publikováno v: Journal of Clinical Oncology. 40:317-317

317 Background: Androgen receptor signaling inhibitors (ARSi) are emerging as standard treatments for prostate cancer across the disease spectrum. With multiple available agents approved, comparing adverse effects between different therapies may guid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9b0fb74172d2fa4c77d5ed249cb826e6
https://doi.org/10.1200/jco.2022.40.28_suppl.317

Zobrazit plný text záznamu

Impact of hyperthermic intraperitoneal chemotherapy on genomic heterogeneity of peritoneal metastases in stage IV gastroesophageal adenocarcinoma

Autor: Divya Sood, Marie L. Fefferman, Natalie Marie Reizine, Ryan B. Morgan, Cecilia T. Ong, Ankit Dhiman, Kiran Turaga, Daniel V.T. Catenacci, Oliver Eng

Publikováno v: Journal of Clinical Oncology. 40:312-312

312 Background: Programmed death ligand 1 (PD-L1) expression and tumor mutational burden (TMB) are potential biomarkers for response to therapy. Heterogeneity of PD-L1 and TMB has been demonstrated in gastroesophageal adenocarcinoma (GEA) in response

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::51cfa86b30fccac18e9774790ca2df21
https://doi.org/10.1200/jco.2022.40.4_suppl.312

Zobrazit plný text záznamu

Safety and efficacy of combining genotype-guided irinotecan (Iri) with 5FU, leucovorin (LV), oxaliplatin (Ox), and docetaxel (Tax) (gFOLFOXIRITAX): The I-FLOAT phase 1 dose-escalation study for advanced upper GI cancers

Autor: Koosha Paydary, Aurelie Desgardin, Chih-Yi Liao, Ardaman Shergill, Natalie Marie Reizine, Stephanie Moya, Bryan Peterson, Katherine Reyes, Chanelle Robinzine, Belen Martinez-Caro Aguado, Christine Racette, Elena Ignatiev, Anu Radha Neerukonda, Yuan Ji, Blase N. Polite, Daniel V.T. Catenacci

Publikováno v: Journal of Clinical Oncology. 40:316-316

316 Background: 5FU, Ox, Iri, and Tax are each active in upper GI cancers. Triplet cytotoxic therapies (txs) improved survival compared to doublets/singlets. However, combination of all 4 agents (FOLFOXIRITAX) has not been studied. UGT1A1 polymorphis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4a205a4e957d3bd1cc52f2c29ae8567f
https://doi.org/10.1200/jco.2022.40.4_suppl.316

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání